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Vaccines developing immune responses toward surface carbohydrates conjugated to
proteins are effective in preventing infection and death by bacterial pathogens. Traditional
production of these vaccines utilizes complex synthetic chemistry to acquire and conjugate
the glycan to a protein. However, glycoproteins produced by bacterial protein glycosylation
systems are signiﬁcantly easier to produce, and could possible be used as vaccine
candidates. In this work, we functionally expressed the Burkholderia pseudomallei O
polysaccharide (OPS II), the Campylobacter jejuni oligosaccharyltransferase (OTase), and a
suitable glycoprotein (AcrA) in a designerE. coli strainwith a higher efﬁciency for production
of glycoconjugates. We were able to produce and purify the OPS II-AcrA glycoconjugate,
and MS analysis conﬁrmed correct glycan was produced and attached. We observed
the attachment of the O-acetylated deoxyhexose directly to the acceptor protein, which
expands the range of substrates utilized by theOTase PglB. Injection of the glycoprotein into
mice generated an IgG immune response against B. pseudomallei, and this response was
partially protective against an intranasal challenge. Our experiments show that bacterial
engineered glycoconjugates can be utilized as vaccine candidates against B. pseudomallei.
Additionally, our new E. coli strain SDB1 is more efﬁcient in glycoprotein production, and
could have additional applications in the future.
Keywords: glycobiology, vaccines, protein glycosylation, microbiology and biotechnology, molecular biology, mass
spectrometry
INTRODUCTION
Burkholderia pseudomallei, a Gram-negative saprophyte, is the
causative agent for melioidosis and is endemic in Southeast Asia
and Northern Australia (Cheng and Currie, 2005). It is highly
resistant to harsh environmental pressures, and it is classiﬁed as
a potential class B bioterrorism weapon due to its high infectivity
when aerosolized (Silva and Dow, 2013). Several virulence factors
have been identiﬁed, including multiple Type III and VI secretion
systems, toxins, capsular polysaccharide, and lipopolysaccharide
(LPS; Nandi and Tan, 2013). Two different LPS structures named
O-polysaccharide (OPS) I and II are present in B. pseudomallei,
and OPS II was shown to be required for serum resistance and vir-
ulence (Knirel et al., 1992; Perry et al., 1995; DeShazer et al., 1998).
B. pseudomallei has an intrinsically high resistance to several dif-
ferent classes of antibiotics, which increases the potential danger
of this organism. Due to the increasing prevalence of new resis-
tance genes, and the increasing number of cases, new alternatives
to treat and prevent melioidosis are required.
Immunization is one of the best available tools against infec-
tion, and it is signiﬁcantly more cost effective than treatment after
disease has occurred. Three main classes of vaccines are commer-
cially produced. Live attenuated bacteria that have been shown
to be highly effective as vaccine candidates however, drawbacks
such as safety, reactogenicity, stability, and manufacturing remain
problematic (Galen and Curtiss, 2013).Whole-cell-killed bacterial
vaccines are easy to commercially manufacture, but have prob-
lems with stability, long-term protection, and present biosafety
risks in the case of class III pathogens. Puriﬁed surface carbohy-
drates have been utilized as a vaccine candidate, but typically only
produce short-term protection and are not effective in children
or mature individuals (Lockhart, 2003). Traditional conjugate
vaccines, where bacterial surface polysaccharides are chemically
conjugated to a carrier protein, have been demonstrated to be
highly effective. The best example is the Haemophilus inﬂuenzae
type b conjugate vaccine, which has nearly eliminated infections
in vast parts of the world (Pollard et al., 2009). However, man-
ufacturing these conjugate vaccines requires complex synthetic
chemistry for the attachment of the glycan to protein carri-
ers. Additionally, the polysaccharides are either obtained from
the target pathogen, which constitutes a major health hazard,
or by laborious, chemical synthesis. Often, bacterial polysac-
charides are too complex to be synthesized efﬁciently, making
this process economically prohibitive. Finally, chemical attach-
ment of the sugar to the carrier protein can result in large and
heterogeneous conjugates, modifying the native structure, and
thus decreasing the protective nature of the vaccine. Both live
attenuated and killed bacterial vaccines have been tested against
B. pseudomallei, but provide little to no protection against disease
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and mortality in murine virulence models (Peacock et al., 2012).
Additionally, since B. pseudomallei requires class III biosafety facil-
ities, manufacturing glycoconjugates containing glycans from its
native host is challenging and possibly hazardous. Recently, it has
been demonstrated a protein chemically conjugated with the B.
pseudomallei OPS and CPS was able to increase survival against
B. pseudomallei infection (Scott et al., 2014). Additionally, pro-
tection has been demonstrated using B. thailandensis E555 as
a live vaccine due to homology of CPS structures (Scott et al.,
2013).
A novel method of synthesizing conjugate vaccines is through
the exploitation of the protein glycosylation machineries of bacte-
ria (Iwashkiw et al., 2012; Cuccui et al., 2013; Wetter et al., 2013).
The cornerstone of bacterial glycosylation is the oligosaccha-
ryltransferase (OTase) enzymes, which covalently attach glycan
structures to either asparagine (N-linked) or serine/threonine
(O-linked) residues (Nothaft and Szymanski, 2010). OTases
have high substrate promiscuity, and thus can transfer a wide
range of glycan structures to acceptor proteins, in a process
called OTase-dependent glycosylation. The best characterized N-
glycosylation system in bacteria is from Campylobacter jejuni
(Nothaft et al., 2010). Brieﬂy, a unique initiating glycosyltrans-
ferase attaches a nucleotide-activated monosaccharide-1P to the
lipid carrier undecaprenyl phosphate (Und-P) in the cytoplas-
mic face of the inner membrane. Subsequently, a series of
other glycosyltransferases attach additional monosaccharides to
ﬁrst residue, and when completed, the lipid-linked oligosac-
charide (LLO) is translocated to the periplasmic face of the
inner membrane by a ﬂippase. Finally, PglB (N-OTase) cova-
lently attaches the glycan to asparagine residues with the sequon
D/E-X-N-Y-S/T (X,Y =P; Kowarik et al., 2006). Earlier stud-
ies demonstrated PglB has relaxed glycan speciﬁcity, allowing
the transfer of a vast array of glycans, including O anti-
gens, to acceptor proteins (Feldman et al., 2005). It was later
shown that O-OTases share this feature (Faridmoayer et al.,
2008). Thus, bacterial glycosylation systems can be exploited
to synthesize novel glycoconjugates for vaccination and diag-
nostic purposes as previously demonstrated (Ihssen et al., 2010;
Iwashkiw et al., 2012; Cuccui et al., 2013; Wetter et al., 2013;
Wacker et al., 2014). Glycoconjugates produced by this method
are signiﬁcantly less expensive, less challenging to produce,
and produce less hazardous waste than conventional chemical
methods.
In this work, we demonstrate that the biosynthesis of the B.
pseudomallei OPS II can be reconstituted in Escherichia coli (E.
coli). Successful generation of the conjugate required the expres-
sion of the corresponding B. pseudomallei OPS II genes in an E.
coli strain lacking both the waaL ligase and wecA initiating gly-
cosyltransferase (SDB1). This glycoconjugate, when injected into
mice, was able to develop a directed IgG immune response toward
B. pseudomallei, and provide partial protection against infection
in a murine model of melioidosis.
MATERIALS AND METHODS
BACTERIAL STRAINS, PLASMIDS, AND GROWTH CONDITIONS
Escherichia coli strains were grown on LB broth at 37◦C. Trimetho-
prim (100 μg/ml), spectinomycin (80 μg/ml), and ampicillin
(100 μg/ml) were added to the media for plasmid selection as
needed. The strains and plasmids used are listed in Table 1.
WESTERN BLOTTING
Glycan expression and glycosylation were analyzed by SDS-PAGE
on 10% gels. The gels were electroblotted onto a nitrocellulose
membrane via semi-dry membrane transfer and analyzed with
antibodies α-His (Santa Cruz Biotechnology) and α-BPs OPSII
glycan kindly provided by Dr. Joanne Prior (1:1,000). Membranes
were visualized using the Odyssey Infrared Imaging System (Li-
Cor Biosciences, USA).
CLONING AND EXPRESSION OF Burkholderia pseudomallei TYPE II OPS
Toobtain the plasmid expressing the type IIO-antigen polysaccha-
ride of Burkholderia pseudomallei under an arabinose promoterwe
used thepCC1FOS-BPF16β_E10vector kindly providedbyProfes-
sor R. Titball (University of Exeter), which contains the LPS cluster
of B. pseudomallei K96243, coordinates 3191324–3229257. The
pCC1FOS-BPF16β_E10 vector was digested with NheI, KpnI, and
PciI to get an 8673 bp fragment, corresponding to genes between
rmlD and wbiC, and with SnaBI and KpnI to get a 9367 bp frag-
ment that includes the genes between wbiC and wbiI. These two
fragments containing the 15 genes required for B. pseudomallei
type II OPS expression were inserted into pBAD24 digested with
NheI and SmaI. Arabinose-dependent expression of the type II
O-antigen was conﬁrmed by Western blot.
CONSTRUCTION OF SDB1 waaL AND wecA DEFICENT STRAIN
Construction of SDB1 strain was done using the P1 trans-
duction protocol adapted from Thomason et al. (2007). The
P1 bacteriophage was ﬁrst grown on the strain (BW25113
rfe::kan.) from the Keio collection library (Baba et al., 2006).
This strain has a kanamycin-resistant cassette on the wecA gene
as a donor. The resulting phage lysate was used to infect the
recipient strain CLM24 (waaL). Recombinant strains were
conﬁrmed by PCR using the oligonucleotides rfe for comp
(5′-GCAATGACCAAGACCAATGACG-3′) and rfe rev comp (5′-
GCTGCTGCGAGTAATATCCC-3′). The kanamycin cassette was
removed using the FLP recombinase expressed from pFLP2.
PRODUCTION AND PURIFICATION OF GLYCOSYLATED AcrA
SDB1 strain transformed with C. jejuni PglB (pMAF10), AcrA
(pIH18), and BPs type II O-antigen (pEQ3) was grown overnight
at 37◦C. Culture was reinnoculated 1/33 into fresh LBmedia using
a culture/ﬂask ratio 1:10. After 2 h at 37◦Cwith shaking at 200 rpm,
the cultures were induced with 0.1 mM isopropyl 1-thio-β-D-
galactopyranoside (IPTG; Sigma) and 0.2% (w/v) L-(+)-arabinose
(MP Biomedicals). To increase the glycosylation yield in SDB1,
we also added MnCl2 (4 mM). Five hours after induction at
37◦C, arabinose was added again to ensure PglB expression. Cells
were harvested by centrifugation after an overnight induction
period and the periplasmic extract containing the glycopro-
teins was extracted using a lysozyme treatment as described
previously (Iwashkiw et al., 2012). For puriﬁcation, the periplas-
mic fraction was equilibrated with 1/9 vol 10× loading buffer
(0.1 M imidazole, 3 M NaCl, 0.2 M Tris-HCl, pH 8.0) and sub-
jected to a Ni2+afﬁnity chromatography as described (Iwashkiw
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Table 1 | List of strains and plasmids utilized.
Strain Genotype or description Reference
EPI300 F-mcrA (mrr-hsdRMS-mcrBC) 80dlacZM15 lacX74 recA1 endA1 araD139 (ara, leu)7697
galU galK λ-rpsL (StrR) nupG trfA dhfr
Epicentre
Top 10 F-mcrA (mrr-hsdRMS-mcrBC) ϕ80lacZM15 lacX74 nupG recA1 araD139 (ara-leu)7697
galE15 galK16 rpsL(StrR) endA1 λ−
Invitrogen
CLM24 W3110, waaL ligase Feldman et al. (2005)
CLM37 W3110, wecA Linton et al. (2005)
BW25113 rfe::kan F-(araD-araB)567 lacZ4787(::rrnB-3) LAM-rph-1 (rhaD-rhaB)568 hsdR514 Baba et al. (2006)
SDB1 W3110, waaL ligase, wecA GalNAc transferase This study
Plasmids
pBAD24 Cloning and expression vector, Arabinose inducible, AmpR Guzman et al. (1995)
pEXT21 Cloning and expression vector, IPTG inducible, SpR Dykxhoorn et al. (1996)
pMLBAD Cloning and expression vector, Arabinose inducible, TpR Lefebre and Valvano (2002)
pEQ3 B. pseudomallei type II OPS, ApR This study
pIH18 Soluble periplasmic C. jejuni acrA6xHis cloned into pEXT21, SpR Hug et al. (2010)
pMAF10 C. jejuni pglB cloned into pMLBAD, TpR Feldman et al. (2005)
pFLP2 Source of Flp recombinase, ApR Hoang et al. (1998)
pCA24N-waaL E. coli waaL cloned into pCA24N from ASKA library; CmR Kitagawa et al. (2005)
pCA21 E. coli wecA cloned into pEXT21, SpR Alaimo et al. (2006)
pJHCV32 HindlIl cosmid clone in pVK102, 07+Tcr Valvano and Crosa (1989)
pCC1FOS-BPF16β_E10 LPS cluster of B. pseudomallei K96243, coordinates 3191324-3229257 Titball Lab (unpublished)
et al., 2012). Puriﬁed protein was quantiﬁed by Bradford assay
(BioRad).
SUGAR QUANTIFICATION OF GLYCOPROTEINS
The protocol was adapted from Dubois et al. (1956). In a small
glass tube was mixed 10 μl of sample, 90 μl of ddH2O, and 100 μl
of freshly made 5% phenol in ddH2O. Then 1 ml of concentrated
H2SO4 was briskly added into themixture and immediately vortex
for several seconds. An orange color with intensity proportional
to concentration began to develop and reached a maximum about
2 h at 30◦C. The samples were read against glucose standards at
OD500.
VACCINATION
BALB/c mice (n = 5 per group, 6-week-old female) were immu-
nized with three doses of puriﬁed recombinant bioconjugate
vaccine, carrier protein, or gamma-irradiated killed whole cells
(3 × 104 Burkholderia pseudomallei K96234), via the intraperi-
toneal route (i.p.) over 6 weeks. The doses were administered
with Imject Alum Adjuvant (Thermo Scientiﬁc), not used with
whole killed cells or when noted. Sera samples were collected for
antibody analysis, prior to immunization 2 weeks after vaccina-
tion and boost. The antibody titre of total IgG was analyzed by
ELISA. Brieﬂy, wells of microtiter plates were coated (18 h, 4◦C)
with gamma-irradiated whole Burkholderia pseudomallei cells at a
1/100 dilution in 100μl of coating buffer (0.05MNa2CO3, 0.05M
NaHCO3, pH 9.6) and were then blocked with 2% (w/v) BSA in
PBS for 2 h at 37◦C. Sera samples at a 1/200 dilution in 100 μl
of antibody dilution buffer [2% (w/v) BSA, 0.1% (v/v) Tween
20] were incubated for 1 h at 37◦C. HRP-conjugated goat anti-
mouse IgG at a 1/8000 in antibody dilution buffer was added for
1 h at 37◦C and then the reaction was visualized by the addi-
tion of 100 μl chromogenic substrate (ultra-TMB) for 5 min.
The reaction was stopped with 100 μl H3PO4 and absorbance
at 405 nm was measured using ELISA plate reader. Plates were
washed ﬁve times with washing buffer [0.1% (v/v) Tween 20] after
each step.
INTRANASAL CHALLENGE MODEL
The murine melioidosis infection model used was carried out
under ABSL-3 containment practices. Brieﬂy, female BALB/cmice
were challenged via the i.n. route (50 μl) with approximately
2 × 103 CFU (approximately 10–12 LD50) of B. pseudomallei
K96243. Mice were weighed prior to inoculation and monitored
for 21 days post-infection. Mice were anesthetized, held vertically,
and 50 ml of the inoculum was released into the nares for inhala-
tion. Following challenge, the inoculum was back titrated on agar
plates to conﬁrm delivered dose. Using this model, control mice
died or were euthanized according to predetermined humane end
points 3–6 days post-challenge.
STATISTICS
Survival curves were generated by use of Kaplan–Meier estimators.
The survival distributions of each treatment group vs. control
protein carrier groupwere compared by unpairedT test orMann–
Whitney test using GraphPad Prism version 6.0.
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ETHICS STATEMENT
This study was carried out in accordance with the Canadian ani-
mal care guidelines. The protocols were approved by the Animal
Care and Use Committees of Defence Research and Development
Canada. Mice were anesthetized by intraperitoneal injection of a
sodium pentobarbital solution.
RESULTS
CLONING AND EXPRESSION OF THE B. pseudomallei K96243 O
ANTIGEN POLYSACCHARIDE II (OPS II) LOCUS IN E. coli
Previous work identiﬁed a region consisting of 21 potential open
reading frames, and further investigation identiﬁed a cluster of
15 genes required for the biosynthesis of B. pseudomallei K96243
OPS II (Figure 1A; DeShazer et al., 1998). A previous study
demonstrated by NMR analysis that the structure of OPS II
is a polymer of a disaccharide repeating structure composed
of -3-)-β-D-glucopyranose-(1–3)-α-L-6-deoxy-talopyranose-(1-,
with variable O-methyl and O-acetyl modiﬁcations (Figure 1B;
Perry et al., 1995). In order to recombinantly express the B. pseu-
domallei OPS II in E. coli, the 15 essential genes were subcloned
(genes rmlB to wbiI) from the plasmid pCC1FOS-BPF16β_E10
by restriction digest into the arabinose inducible expression vec-
tor pBAD24, generating pEQ3 (Figure 1A). Expression of the B.
pseudomallei OPS II in E. coli CLM37 was visualized by Western
blot as a typical ladder of immunoreactive bands, conﬁrming the
production of the carbohydrate structure (Figure 1C).
GENERATION OF AN E. coli STRAIN OPTIMIZED FOR OPS II
PRODUCTION AND PROTEIN GLYCOSYLATION
We attempted to generate a N-linked glycoprotein with the OPS
II by exploiting the C. jejuni N-glycosylation system as previously
described (Ihssen et al., 2010; Iwashkiw et al., 2012; Cuccui et al.,
2013; Wetter et al., 2013). In earlier work, N-glycosylated AcrA
was synthesized in E. coli by co-expression of C. jejuni PglB and
AcrA with an appropriate carbohydrate structure. We therefore
expressed PglB (pMAF10), AcrA (pIH18), and the B. pseudomallei
OPS II antigen (pEQ3) in both a traditional expression (EPI300)
andwecA- (CLM37) strains and tested for glycosylationbyWestern
blot. We were unable to detect any evidence of glycosylation of
puriﬁed AcrA (data not shown).
One issue with exploiting O antigens using protein glycosyla-
tion may be the precursor can also be used by the WaaL ligase in
E. coli, thus siphoning off the substrate, and decreasing the glyco-
sylation efﬁciency (Figure 2). Additionally, E. coli strains express
the initiating glycosyl transferase (wecA),which transfers aGlcNAc
onto the undecaprenyl-diphosphate (Und-PP) carrier. This would
interfere with the synthesis of the glycan of interest onto the same
lipid if the ﬁrst sugar in the structure is not a GlcNAc, as in the case
of the OPS II. We hypothesized that deletion of WaaL and WecA
would result in an increased efﬁciency of protein glycosylation
(Figure 2C).
We therefore constructed the E. coli wecA− waaL− mutant
strain SDB1. Using the KEIO strain collection (Baba et al., 2006),
the wecA mutation was transduced into CLM24, an E. coli waaL
mutant (Feldman et al., 2005), creating SDB1. To functionally
conﬁrm the double mutation, we analyzed the LPS produced
by SDB1 transformed with plasmid pJHCV32 (Figure 3). The
plasmid pJHCV32 drives the constitutive expression of the E. coli
O7 antigen, but relies on the chromosomal copy of the glycosyl-
transferase WecA (Valvano and Crosa, 1989). Expression in trans
of either WecA or WaaL individually in this background did not
result in the production of a smooth LPS containing the O7 anti-
gen (lanes 1–8). However, when both genes were co-expressed in
SDB1, we observed the characteristic polymerization of O anti-
gen previously observed for the E. coli O7 LPS (lanes 9 and 10),
conﬁrming the creation of the double mutation.
IN VIVO SYNTHESIS AND PURIFICATION OF AN N-LINKED
GLYCOCONJUGATE WITH THE Burkholderia OPSII GLYCAN
To create an N-linked glycoconjugate, we transformed the E.
coli strain SDB1 with the pEQ3 (OPS II), pMAF10 (PglB), and
pIH18 (AcrA). Cultures of the transformed strain were grown
FIGURE 1 | Description of Burkholderia pseudomallei O-polysaccharide II
(OPSII) cluster. (A) Representation of the required 15 genes for the synthesis
of OPS II and predicted functions. (B) Expected glycan intermediate structure
attached to Undecaprenyl pyrophosphate. (C)Western blot of 10 μl of
whole-cell extracts utilizing an anti-Glycan antibody reveals expression of OPS
II (subcloned in pEQ3) in E. coli produces a polymer in whole-cell extracts.
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FIGURE 2 | Hypothesis for the lack of glycosylation due to glycan
competition and utilization, resulting in the development of the E. coli
strain SDB1. (A)When expressing pEQ3 in aWT E. coli background, OPS II
is produced at a lower quantity than the native O-antigen, and both structures
are preferentially transferred byWaaL to Lipid A, instead of to the acceptor
protein by PglB (OTase). (B) If wecA is deleted, the native O-antigen cannot
be produced, allowing for a greater production of OPS II. However, OPS II
would be still selectively transferred byWaaL over PglB. (C) If both wecA and
waaL are deleted, the OPS II structure would be highly produced, and only
available to PglB for synthesis of glycoproteins.
and induced as required, and AcrA was puriﬁed from periplas-
mic extracts by Ni2+ afﬁnity chromatography. To determine if
AcrA was glycosylated, we analyzed the puriﬁed protein by either
Western blot with antibodies speciﬁc to either AcrA or OPS II, or
Coomassie stain, and when visualized together, we observed an
overlap of the signal, suggesting glycosylation of AcrA with the
OPSII glycan (Figure 4).
To conﬁrm AcrA was glycosylated with the B. pseudomallei
OPS II carbohydrate, we employed mass spectrometry (MS)
techniques. The puriﬁed glycoprotein was tryptically digested in-
solution, and the resulting peptides were examined by LC-ESI-Q-
TOF MS and MS/MS. Manual analysis of the MS data (MassLynx;
Waters Corporation) revealed a peak with an m/z 1152.063+,
and further inspection of this peak by MS/MS revealed a gly-
copeptide that corresponded to the previously identiﬁed second
glycosylation site of AcrA (AVFDNNNSTLLPGAFATITSEGFIQK;
m/z 2754.1) with the addition of an m/z 700.2 modiﬁcation
(Figure 5). De novo peak annotation identiﬁed the modiﬁcation
to be a tetramer of 188–162–188–162. The mass of 188 Da is con-
sistent with an O-acetyl deoxyhexose residue, and the 162 Da is
consistent with a hexose residue. We were also able to identify in
the low-molecular region both an individual O-acetyl deoxyhex-
ose (189.0Da), and a subunit of the dimerwith amass of 351.1Da.
Our MS characterization of the B. pseudomallei OPS II glycan is
consistent with the previously published data identifying it to be a
polymer of dimers of O-acetylated deoxytalose and glucose (Perry
et al., 1995). These data combined with the immunoreactivity of
our glycoconjugate to the B. pseudomallei OPS II antibody con-
ﬁrm that we were able to synthesize and glycosylate AcrA with the
correct glycan structure in E. coli SDB1.
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FIGURE 3 | Confirmation of a wecA- waaL- double mutant (SDB1) in
E. coliW3110.To verify the double mutant, LPS extractions (20 μl per
sample) were analyzed by silverstain for the ability to produce exogenously
expressed E. coli O7 LPS (pJHCV32). No LPS was observed when either
WecA orWaaL was expressed in trans (lanes 1–8). However, when both
were coexpressed, a laddering pattern was observed, conﬁrming
complementation of the double mutant (lanes 9 and 10).
FIGURE 4 | Analysis of purifiedAcrA byWestern Blot. SDB1 transformed
with pMAF10 (pglB), pIH18 (acrA), and pEQ3 (OPS II) were grown (+/−)
induction of OPS II, harvested, and AcrA was puriﬁed by Ni2+-NTA afﬁnity
chromatography. Puriﬁed glycoconjugate was separated on 10% SDS-PAGE
and analyzed by western blot (5 μl) or Coomassie stain (15 μl). A
high-molecular-weight ladder is co-detected by both α-His and α-Glycan
antibodies, and overlap of the two signals strongly suggests glycosylation
of AcrA. Staining of the puriﬁed protein is observed by Coomassie stain.
MICE INJECTED WITH PURIFIED N-LINKED BIOGLYCOCONJUGATE
DEVELOPED A PARTIALLY PROTECTIVE IgG IMMUNE RESPONSE
TOWARD B. pseudomallei WHOLE CELLS
To evaluate the potential use of the glycoprotein as conju-
gate vaccine, the puriﬁed AcrA containing OPS II was injected
intraperitoneally into mice to measure the immune response
compared to whole-cell-killed B. pseudomallei. Groups of ﬁve
mice were injected with PBS, unglycosylated AcrA as control,
glycoconjugate in different quantities, or whole-cell-killed cells.
The IgG immune response was tested by ELISA against whole-
cell extracts of B. pseudomallei (Figure 6). All test groups were
compared to the PBS control, and showed no initial immune
response toward B. pseudomallei in the pre-injection sera. The
AcrA-injected group had a slight increase in IgG response, but did
not increase after additional boosts. A signiﬁcant increase in IgG
response was observed in each of the glycosylated test groups after
the primary vaccination, with varying degrees of improvement in
immune response after a second and third boost. The best immune
response was observed in the mice injected with whole-cell lysates
of B. pseudomallei had a signiﬁcantly stronger immune response
as compared to the glycoconjugate sera, but this was expected as
whole cells were use as antigen for the ELISA.
We next tested the immunized mice for a preliminary eval-
uation of the efﬁcacy of the glycoconjugate. We employed an
intranasal murine melioidosis model against B. pseudomallei
infection with a dose of 12× LD50 (Figure 7). Mice vaccinated
with only protein carrier died orwere euthanized according to pre-
determined humane end points after 6 days. For the PBS-injected
control group, 80% of the mice died or were euthanized after
6 days, and onemouse survived until day 13 of the challenge. All of
the mice vaccinated with the glycoconjugate showed a signiﬁcant
increase in survival time as compared to the control protein carrier
group. However, contrary to the ELISA results that showed the best
IgG immune response inmice vaccinatedwith 2μg of glycosylated
AcrA, 40% of the mice survived until day 12, with the remaining
being sacriﬁced on day 14. Mice injected with 1 μg of glycopro-
tein without any adjuvant saw survival until day 18, while one
mouse vaccinated with 1 μg survived until day 22. The difference
in mean time to death was not statistically signiﬁcant between the
groups receiving the various glycoprotein preparations. In com-
paring our glycoconjugate to whole-cell-killed bacteria as vaccine
candidates, we observed highly similar survival of the mice, with
all mice succumbing to infection by day 18 of the challenge. Over-
all, these results demonstrate that theN-glycoconjugate containing
the B. pseudomallei OPS II is capable of providing partial immune
protection against a 12 × LD50 dose, and it is comparable to
whole-cell-killed bacteria in protection against infection.
DISCUSSION
Due to a combination of factors including the increasing num-
ber of reported cases of B. pseudomallei infections, the risk posed
by the bacterium as a potential biological warfare agent, and an
absence of an effective vaccine, we explored the possibility that
by exploiting the N-linked glycosylation system of C. jejuni, we
could produce a glycoconjugate vaccine containing the OPS II
of B. pseudomallei. This strategy was only demonstrated in a few
cases (Iwashkiw et al., 2012; Cuccui et al., 2013;Wetter et al., 2013).
SinceB. pseudomallei is a biosafety class III agent wewere unable to
directly exploit the nativeOPS II by expressing theN-glycosylation
system in the host as previously shown (Iwashkiw et al., 2012).
Instead, we utilized previous knowledge of the genetic loci respon-
sible for the biosynthesis of OPS II (DeShazer et al., 1998), and
subcloned the key 15 genes into an E. coli expression vector. We
observed high levels of expression of the OPS II in E. coli strains
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FIGURE 5 | Mass spectrometry identification of the B. pseudomallei
OPS II glycan attached to AcrA. MS analysis of tryptically digested
glycosylated AcrA revealed a peak of m/z 1152.063+. MS/MS of this
peak showed a previously characterized glycosylation site of AcrA
(AVFDNNNSTLLPGAFATITSEGFIQK; 2754.1 Da) with a modiﬁcation of
700.2 Da. Analysis of the modiﬁcation revealed a tetrameric glycan,
with a structure of 188–162–188–162. This structure is consistent with
the previously determined structure of B. pseudomallei OPS II being a
polymer of dimers of O-acetylated deoxytalose (188 Da) and glucose
(162 Da).
by Western blot, and attempted to create the glycoconjugate in a
basic expression and wecA- E. coli strains as previously described
(Ihssen et al., 2010; Cuccui et al., 2013;Wetter et al., 2013). We did
not observe any evidence of glycosylation, and hypothesized that
the OPS II was being utilized exclusively tomodify the LPS. There-
fore, we engineered an E. coli strain (SDB1) lacking both the waaL
ligase, and wecA. Construction of the SDB1 strain was conﬁrmed
by expressing either or bothWecAandWaaLwith a plasmid encod-
ing the E. coli O7 LPS cluster that lacksWecA homolog. Analysis of
LPS extractions by silverstain showed that theO7 antigen structure
was only transferred to lipid A in the presence of both enzymes.
Our engineered strain in theory should be able to produce the
OPS II-AcrA glycoconjugate with high efﬁciency due to no other
competition for either the undecaprenyl-phosphate lipid carrier
by WecA or the OPS II-Und-PP substrate from WaaL.
We showed that SDB1 produced the desired glycoconjugate
whenOPS II (pEQ3), PglB (pMAF10), andAcrA (pIH18) were co-
expressed. The generation of the conjugate was shown viaWestern
blot andMS. Interestingly, glycosylationofAcrA required the addi-
tion of MnCl2 to the media. Although Mn2+ is required for PglB
activity and was observed in the active site of the crystal structure
(Lizak et al., 2011), we did not have to add Mn2+ to obtain glyco-
sylated proteins in previous experiments. The direct relationship
between its addition and glycosylation efﬁciency is unclear. The
MS examination of the puriﬁed glycoconjugate revealed the pres-
ence of a tetrameric glycan moiety corresponding to two repeats
of O-acetylated deoxyhexose and hexose, in agreement with pre-
viously published characterization of the structure (Perry et al.,
1995). Interestingly, previous work has shown that the C. jejuni
OTase PglB can only transfer glycans with a reducing monomer
with an N-acetyl group, whereas the B. pseudomallei OPS II struc-
ture has been shown to possess an O-acetyl modiﬁcation. This
ﬁnding expands our knowledge on the substrate speciﬁcity of PglB.
We did not observe any larger glycan structures that were detected
by Western blot, but this could be due to limitations of our MS
instruments. Most of the Wzy-independent glycans require an
adapter composed of two monosaccharides linking the lipid car-
rier to the polymeric structure (Whitﬁeld, 2006; Greenﬁeld and
Whitﬁeld, 2012). The ﬁnding that the O-acetylated deoxytalose
appears to be directly linked to the protein indicates that a linker
glycan (proposed in Figure 1A as X1 and X2) is not present in
the OPS II structure. Our experiments demonstrate that in the
genetically engineered strain SDB1, we were able to produce a
glycoconjugate with the B. pseudomallei OPS II carbohydrate.
We carried out preliminary experiments to determine if our
glycoconjugate could be utilized as a vaccine against B. pseudo-
mallei. We injected different quantities of the glycoconjugate into
mice. We observed virtually no response toward B. pseudomallei
for the mice injected with the protein carrier alone, whereas a sig-
niﬁcantly stronger response from themice injected with all groups
of the glycoconjugate. Interestingly, an intermediate response was
observed in the 1μg glycoconjugate groups, regardless of the addi-
tion of an adjuvant. We then challenged the vaccinated mice with
B. pseudomallei K96243, and after 6 days post challenge, none
of the carrier control injected mice survived, whereas survival
was observed each of the glycoconjugate groups, with the longest
survival in the 1 μg group, irrespective of the addition of an adju-
vant. Why lower levels of antibody production resulted in better
protection remains unknown, although these differences in pro-
tection were not statistically signiﬁcant between groups receiving
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FIGURE 6 | ELISA of the IgG immune response of immunized mice
toward whole-cell extracts of B. pseudomallei. All data were
normalized to the PBS-injected control mice, and no response was
observed in all groups prior to immunization. A low level of response
was observed at a consistent level for the unglycosylated AcrA control,
whereas all test groups injected with glycosylated AcrA had a
signiﬁcant IgG response. The results are the median of ﬁve mice in
each test group.
the glycoprotein. It is possible that the carrier protein, AcrA, due
to its high immunogenic nature, acts as an adjuvant itself. This
could also possibly explain why both of the 1 μg groups while
having a lower detected IgG immune response compared to the
2 μg group have a longer survival period. Our results are con-
sistent with these previous studies with the non-protected mice
succumbing to infection after ∼1 week (Nelson et al., 2004; Su
et al., 2010; Nieves et al., 2011). Interestingly, our initial studies
with the glycoconjugate gave similar protection levels to whole-
cell-killed B. pseudomallei. Further optimization of our vaccine
candidate is currently undergoing. This includes testing different
amounts of conjugate, and replacing the acceptor protein from
AcrA of C. jejuni to a B. pseudomallei protein, which may enhance
the immunogenicity of the conjugate.
Several other studies havebeenpublished attempting todevelop
a vaccine against B. pseudomallei (reviewed in Silva and Dow,
2013). Many of these vaccine candidates have dealt with either
attenuated strains, whole-cell-killed bacteria, or puriﬁed proteins
directly from B. pseudomallei, which requires class III biosafety
facilities, and would lead to higher signiﬁcant problems for
commercialization of the product. Other groups attempted to
recombinantly express and purify B. pseudomallei proteins in
E. coli, with limited success. However, our work has demon-
strated that the OPS II carbohydrate of B pseudomallei can be
functionally expressed in E. coli, and be utilized by PglB to
create a glycoconjugate that is partially protective against infec-
tion. Glycoengineered therapeutics are simple to produce, cost
effective, and have been demonstrated to provide long-term pro-
tection against several pathogens. Additionally, previous work
has used a similar glycoconjugate with the Y. enterocolitica O9
O-antigen as a diagnostic tool (Iwashkiw et al., 2012). Conju-
gation of the glycoconjugate to magnetic nanobeads has shown
signiﬁcant promise in detection of disease in cattle and human
sera samples (Ciocchini et al., 2013, 2014). A similar system may
have future potential for diagnosing individuals infected with B.
pseudomallei.
In summary, we have demonstrated that the OPS II glycan of
B. pseudomallei can be functionally expressed in E. coli. Addition-
ally, this glycan was transferred to the carrier protein AcrA by the
OTase PglB, both from C. jejuni, to generate a glycoconjugate. We
also described a novel E. coli strain SDB1 which lacks wecA and
waaL, resulting in a higher efﬁciency of glycosylation as compared
to previously used strains. Mice injected with this glycoprotein
were able to develop a long-term IgG immune response, and
showed signiﬁcantly longer survival when challengedwithB. pseu-
domallei as compared to the naive controls. This new biologically
engineered strain may be used for the future creation of commer-
cial bioglycoconjugate therapeutics, and glycoconjugate may have
future potential for diagnostic applications or vaccination against
B. pseudomallei infections.
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FIGURE 7 | Murine survival of different test groups to a 12× LD50 i.n.
challenge of B. pseudomallei. Mice vaccinated with either PBS or
unglycosylated AcrA controls had a signiﬁcantly lower survival period as
compared to the mice injected with OPS II glycosylated AcrA. Interestingly,
mice vaccinated with 1 μg glycoconjugate (+/− adjuvant) had a higher
survivorship percentage as compared to the 2 μg vaccinated group.
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